During the last session, Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s traded shares were 2.01 million, with the beta value of the company hitting 1.22. At the end of the trading day, the stock’s price was $14.48, reflecting an intraday gain of 0.70% or $0.1. The 52-week high for the SNDX share is $25.16, that puts it down -73.76 from that peak though still a striking 16.71% gain since the share price plummeted to a 52-week low of $12.06. The company’s market capitalization is $1.25B, and the average trade volume was 2.52 million shares over the past three months.
Syndax Pharmaceuticals Inc (SNDX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.20. SNDX has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.04.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) trade information
Syndax Pharmaceuticals Inc (SNDX) registered a 0.70% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.70% in intraday trading to $14.48, hitting a weekly high. The stock’s 5-day price performance is -7.00%, and it has moved by 0.98% in 30 days. Based on these gigs, the overall price performance for the year is -38.93%.
The consensus price target of analysts on Wall Street is $27.5, which implies an increase of 47.35% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $37 respectively. As a result, SNDX is trading at a discount of -155.52% off the target high and -24.31% off the low.
Syndax Pharmaceuticals Inc (SNDX) estimates and forecasts
In the rating firms’ projections, revenue will increase 209.66% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 11.36M as predicted by 11 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 14.08M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -15.16%. While earnings are projected to return -4.49% in 2025, the next five years will return 26.95% per annum.
SNDX Dividends
Syndax Pharmaceuticals Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 7.34 million shares, is of WELLINGTON MANAGEMENT GROUP LLP’s that is approximately 8.6125% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $150.67 million.
Also, the Mutual Funds coming in first place with the largest holdings of Syndax Pharmaceuticals Inc (SNDX) shares are Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund . Data provided on Oct 31, 2024 indicates that Vanguard Specialized-Health Care Fund owns about 2.99 shares. This amounts to just over 3.50 percent of the company’s overall shares, with a $43.26 million market value. The same data shows that the other fund manager holds slightly less at 2.6, or about 3.05% of the stock, which is worth about $37.66 million.
